Research programme: fluoroquinolone antibacterials - Wakunaga

Drug Profile

Research programme: fluoroquinolone antibacterials - Wakunaga

Alternative Names: Wfq-101; WFQ-228; WQ-2932; WQ-3335

Latest Information Update: 01 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wakunaga Pharmaceutical
  • Class Fluoroquinolones; Small molecules
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections; Pneumococcal infections

Most Recent Events

  • 16 Jun 2016 Antimicrobial data from a preclinical trial presented at the ASM Microbe 2016 (ASM-2016)
  • 17 Oct 2007 This programme is still undergoing active development
  • 25 Jan 2006 Data presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2005) have been added to the adverse events, pharmacokinetics and Bacterial infections pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top